Tempest Therapeutics (TPST)
(Delayed Data from NSDQ)
$3.44 USD
-0.10 (-2.82%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $3.44 0.00 (0.00%) 4:38 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Balance Sheet
Fiscal Year End for Tempest Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 39 | 31 | 52 | 39 | 64 |
Receivables | 0 | 0 | 0 | 0 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 2 | 17 | 2 | 6 |
Total Current Assets | 40 | 33 | 69 | 41 | 71 |
Net Property & Equipment | 1 | 1 | 1 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 1 |
Total Assets | 52 | 46 | 73 | 43 | 75 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 1 | 1 | 1 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 3 | 5 | 18 | 6 | 9 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 9 | 7 | 20 | 8 | 13 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 6 | 10 | 15 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 25 | 28 | 37 | 10 | 15 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 192 | 154 | 136 | 278 | 267 |
Retained Earnings | -165 | -136 | -100 | -245 | -209 |
Other Equity | 0 | 0 | 0 | 1 | 1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 27 | 18 | 36 | 34 | 60 |
Total Liabilities & Shareholder's Equity | 52 | 46 | 73 | 43 | 75 |
Total Common Equity | 27 | 18 | 36 | 34 | 60 |
Shares Outstanding | 19.20 | 10.50 | 6.90 | 1.20 | 1.20 |
Book Value Per Share | 1.39 | 1.72 | 5.23 | 28.11 | 49.89 |
Fiscal Year End for Tempest Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 39 | 11 | 18 | 23 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 1 | 1 | 1 | 2 |
Total Current Assets | NA | 40 | 12 | 19 | 25 |
Net Property & Equipment | NA | 1 | 1 | 1 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 52 | 24 | 31 | 37 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 1 | 1 | 1 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 3 | 3 | 3 | 3 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 4 | 2 | 3 | 2 |
Total Current Liabilities | NA | 9 | 7 | 9 | 8 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 6 | 8 | 7 | 9 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 25 | 25 | 26 | 26 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 192 | 157 | 156 | 154 |
Retained Earnings | NA | -165 | -158 | -151 | -143 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 27 | -1 | 5 | 11 |
Total Liabilities & Shareholder's Equity | NA | 52 | 24 | 31 | 37 |
Total Common Equity | 0 | 27 | -1 | 5 | 11 |
Shares Outstanding | 22.10 | 19.20 | 13.30 | 11.50 | 10.50 |
Book Value Per Share | 0.00 | 1.39 | -0.09 | 0.44 | 1.04 |